Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 2
2005 1
2007 2
2008 1
2010 3
2011 14
2012 5
2013 11
2014 9
2015 10
2016 10
2017 8
2018 9
2019 6
2020 11
2021 10
2022 10
2023 22
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

146 results

Results by year

Filters applied: . Clear all
Page 1
Epigenetic signature and key transcriptional regulators of human antigen-specific type 1 regulatory T cells.
Cepika AM, Amaya L, Waichler C, Narula M, Mantilla MM, Thomas BC, Chen PP, Freeborn RA, Pavel-Dinu M, Nideffer J, Porteus M, Bacchetta R, Müller F, Greenleaf WJ, Chang HY, Roncarolo MG. Cepika AM, et al. Among authors: muller f. bioRxiv [Preprint]. 2024 Mar 12:2024.03.07.582969. doi: 10.1101/2024.03.07.582969. bioRxiv. 2024. PMID: 38559096 Free PMC article. Preprint.
CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.
Müller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Völkl S, Aigner M, Rothe T, Minopoulou I, Tur C, Knitza J, Kharboutli S, Kretschmann S, Vasova I, Spoerl S, Reimann H, Munoz L, Gerlach RG, Schäfer S, Grieshaber-Bouyer R, Korganow AS, Farge-Bancel D, Mougiakakos D, Bozec A, Winkler T, Krönke G, Mackensen A, Schett G. Müller F, et al. N Engl J Med. 2024 Feb 22;390(8):687-700. doi: 10.1056/NEJMoa2308917. N Engl J Med. 2024. PMID: 38381673
Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee.
Greco R, Alexander T, Del Papa N, Müller F, Saccardi R, Sanchez-Guijo F, Schett G, Sharrack B, Snowden JA, Tarte K, Onida F, Sánchez-Ortega I, Burman J, Castilla Llorente C, Cervera R, Ciceri F, Doria A, Henes J, Lindsay J, Mackensen A, Muraro PA, Ricart E, Rovira M, Zuckerman T, Yakoub-Agha I, Farge D. Greco R, et al. Among authors: muller f. EClinicalMedicine. 2024 Feb 10;69:102476. doi: 10.1016/j.eclinm.2024.102476. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38361991 Free PMC article. Review.
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma.
Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, Oliver-Caldés A, Stölzel F, Rathje K, Fischer L, Born P, Schäfer L, Albici AM, Schub N, Kfir-Erenfeld S, Assayag M, Asherie N, Wulf GG, Kharboutli S, Müller F, Shune L, Davis JA, Anwer F, Vucinic V, Platzbecker U, Ayuk F, Kröger N, Khouri J, Gurnari C, McGuirk J, Stepensky P, Abdallah AO, Fernández de Larrea C. Gagelmann N, et al. Among authors: muller f. J Clin Oncol. 2024 Feb 15:JCO2302232. doi: 10.1200/JCO.23.02232. Online ahead of print. J Clin Oncol. 2024. PMID: 38358946
Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic B-lineage leukaemia in children and young adults.
Feuchtinger T, Bader P, Subklewe M, Breidenbach M, Willier S, Metzler M, Gökbuget N, Hauer J, Müller F, Schlegel PG, Frühwald M, Schmid C, Troeger A, Baldus C, Meisel R, Künkele A, Topp M, Bourquin JP, Cario G, Von Stackelberg A, Peters C. Feuchtinger T, et al. Among authors: muller f. Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.283780. Online ahead of print. Haematologica. 2024. PMID: 38356450 Free article.
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality.
Rejeski K, Wang Y, Hansen DK, Iacoboni G, Bachy E, Bansal R, Penack O, Müller F, Bethge W, Munoz J, Mohty R, Bücklein VL, Barba P, Locke FL, Lin Y, Jain MD, Subklewe M. Rejeski K, et al. Among authors: muller f. Blood Adv. 2024 Apr 23;8(8):1857-1868. doi: 10.1182/bloodadvances.2023011767. Blood Adv. 2024. PMID: 38181508 Free PMC article.
Comment on: Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T-cells after failure of several B cell depleting antibodies: reply.
Taubmann J, Knitza J, Müller F, Völkl S, Aigner M, Kretschmann S, Atzinger A, Kuwert T, Mackensen A, Schett G. Taubmann J, et al. Among authors: muller f. Rheumatology (Oxford). 2023 Dec 21:kead669. doi: 10.1093/rheumatology/kead669. Online ahead of print. Rheumatology (Oxford). 2023. PMID: 38127905 No abstract available.
146 results